Literature DB >> 12118523

Metallo-beta-lactamase VIM-2 in clinical isolates of Pseudomonas aeruginosa from Portugal.

Olga Cardoso1, Rui Leitão, Alexandra Figueiredo, João Carlos Sousa, Aida Duarte, Luísa Vieira Peixe.   

Abstract

Resistance to carbapenems is emerging, and it is a great problem to therapeutics. Three isolates of Pseudomonas aeruginosa from a Portuguese hospital identified in urine and sputum, in 1995, presented a high-level resistance to imipenem (> 32 mg/L). Afterward, one isolate of P. aeruginosa recovered from urine of an ambulatory patient in 1998 showed high resistance to imipenem and meropenem. The resistance to carbapenems in these strains was associated with the production of a class B beta-lactamase, as was demonstrated by imipenem hydrolysis and inhibition by EDTA. Using primers described for bla(IMP) and bla(VIM), the amplification of the latter was observed in all isolates and a VIM-2 metallo-enzyme was identified. The pulsed-field gel electrophoresis (PFGE) patterns of these isolates were indistinguishable, suggesting dissemination to the community of this VIM-2 producer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118523     DOI: 10.1089/107662902760190635

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  21 in total

1.  Regional spread of Pseudomonas aeruginosa ST357 producing IMP-7 metallo-β-lactamase in Central Europe.

Authors:  Jaroslav Hrabák; Dana Cervená; Radoslaw Izdebski; Wojciech Duljasz; Marek Gniadkowski; Marta Fridrichová; Pavla Urbásková; Helena Zemlicková
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

2.  First isolation of bla(VIM-2) in Klebsiella oxytoca clinical isolates from Portugal.

Authors:  T Conceição; A Brízio; A Duarte; R Barros
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Characterization of In100, a new integron carrying a metallo-{beta}-lactamase and a carbenicillinase, from Pseudomonas aeruginosa.

Authors:  Sandra Quinteira; João Carlos Sousa; Luísa Peixe
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  First isolation of blaVIM-2 in an environmental isolate of Pseudomonas pseudoalcaligenes.

Authors:  Sandra Quinteira; Helena Ferreira; Luísa Peixe
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

5.  Multiniche screening reveals the clinically relevant metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa far from the hospital setting: an ongoing dispersion process?

Authors:  Sandra Quinteira; Luísa Peixe
Journal:  Appl Environ Microbiol       Date:  2006-05       Impact factor: 4.792

6.  First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.

Authors:  Wojciech Duljasz; Marek Gniadkowski; Silvia Sitter; Alexandra Wojna; Crista Jebelean
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

7.  Blue-carba, an easy biochemical test for detection of diverse carbapenemase producers directly from bacterial cultures.

Authors:  J Pires; A Novais; L Peixe
Journal:  J Clin Microbiol       Date:  2013-10-09       Impact factor: 5.948

8.  Complete Sequence of p07-406, a 24,179-base-pair plasmid harboring the blaVIM-7 metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States.

Authors:  Hongyang Li; Mark A Toleman; Peter M Bennett; Ronald N Jones; Timothy R Walsh
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

Review 9.  Metallo-beta-lactamases: the quiet before the storm?

Authors:  Timothy R Walsh; Mark A Toleman; Laurent Poirel; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

10.  Molecular epidemiology of acquired-metallo-beta-lactamase-producing bacteria in Poland.

Authors:  Janusz Fiett; Anna Baraniak; Agnieszka Mrówka; Malgorzata Fleischer; Zuzanna Drulis-Kawa; Łukasz Naumiuk; Alfred Samet; Waleria Hryniewicz; Marek Gniadkowski
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.